Platinum-free treatment for nasopharyngeal cancer
This trial tests a treatment without platinum (a standard chemotherapy drug) for people with a certain type of nose or throat cancer. It aims to see if this approach is effective and safe, potentially offering a new option with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have newly diagnosed nasopharyngeal carcinoma (a type of nose or throat cancer) that is stage II or III.
- You must be in good general health, with normal blood, liver, and kidney function.
- You must not have certain infections like HIV, hepatitis B or C, or active tuberculosis.
- You must not have serious heart problems, other active cancers, or a history of significant autoimmune disease.
- You must agree to use reliable contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of an oral targeted therapy (anlotinib) plus immunotherapy and standard chemoradiation for people with high-risk nasopharyngeal cancer. The goal is to see if this approach is more effective than standard treatment.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.